QWQijia Wei

Qijia Wei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qijia Wei has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Author Correction: Posttranslational modifications remodel proteome-wide ligandability

    by Weichao Li, Qijia Wei, Manuel Llanos, Clara Gathmann, Paolo Governa, Tzu-Yuan Chiu, Jacob M. Wozniak, Appaso M. Jadhav, Matthew Holcomb, Jacob Cravatt, et al.


  • Open Access

    Posttranslational modifications remodel proteome-wide ligandability

    by Weichao Li, Qijia Wei, Manuel Llanos, Clara Gathmann, Paolo Governa, Tzu-Yuan Chiu, Jacob M. Wozniak, Appaso M. Jadhav, Matthew Holcomb, Jacob Cravatt, et al.

    Posttranslational modifications (PTMs) vastly expand the diversity of the human proteome, dynamically reshaping protein activity, interactions and localization in response to environmental, pharmacologic and disease-associated cues. However, their proteome-wide impact on small-molecule recognition—and, thus, druggability—remains largely unexplored. Here we present a chemical proteomic strategy to delineate how PTM states remodel protein ligandability in human cells. Using broad-spectrum photoaffinity probes, we identified more than 400 functionally diverse proteins whose ability to engage small molecules is impacted by phosphorylation or N-linked glycosylation status. Integrating binding site mapping with structural analyses reveals a diverse array of PTM-dependent pockets. Among these, we discovered that the phosphorylation status of common oncogenic KRAS mutants impacts the action of small molecules, including clinically approved inhibitors. These findings illuminate a previously underappreciated layer of proteome plasticity governed by PTMs and highlight opportunities to develop chemical probes that selectively target proteins in defined modification states. The alternative text for this image may have been generated using AI.


  • Open Access

    An O-glycopeptide participates in the formation of distinct Aβ42 fibril structures and attenuates Aβ42 neurotoxicity

    by Qijia Wei, Dangliang Liu, Wencheng Xia, Fengzhang Wang, Lu Huang, Jun Zhang, Xiaoya Wang, Zhongxin Xu, Changdong He, Wenzhe Li, et al.

    The self-assembly of biomolecules through noncovalent interactions is critical in both physiological and pathological processes, as exemplified by the assembly of amyloid β peptide (Aβ) into oligomers or fibrils in Alzheimer’s disease (AD). Developing molecules that can modulate this assembly process holds significant mechanistic and therapeutic potential. In this study, we identified glycopeptides as a class of protein aggregation modulators, showing that β-N-acetylgalactosamine (β-GalNAc)-modified Aβ9-21 promotes Aβ42 fibrillation while reducing its toxic oligomers. Using biochemical assays, cryo-EM, and molecular dynamics simulations, we demonstrated that β-GalNAc-modified Aβ9-21 coassembles with Aβ42, forming unique fibril structures stabilized by both hydrophobic interactions and an organized hydrogen bond network facilitated by the glycopeptide. Importantly, β-GalNAc-modified Aβ9-21 can alleviate the neurotoxicity of Aβ42 in neuronal cells and an AD male mouse model. These findings underscore the potential of glycopeptides in regulating amyloid aggregation and provide structural insights for designing molecules targeting amyloid-related pathologies.